Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.72 |
| ▸ | NPY2R | P49146 | 10/20 | 0.69 |
| ▸ | NPY4R | P50391 | 8/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY1R | P25929 | 8/20 | 0.69 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.68 |
| ▸ | GLP1R | P43220 | 3/20 | 0.64 |
| ▸ | GCGR | P47871 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496288 | 0.95 | NPY2R (0.74) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| Human Neuropeptide Y SCHEMBL29780330 | 0.94 | NPY2R (0.79) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29571016 | 0.94 | NPY2R (0.70) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29496391 | 0.94 | NPY2R (0.72) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29440046 | 0.92 | CRHR1 (0.77) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29526997 | 0.92 | NPY2R (0.72) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL13248707 | 0.92 | NPY2R (0.80) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| Neuropeptide-Y SCHEMBL3051623 | 0.91 | NPY2R (0.82) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29570760 | 0.91 | NPY2R (0.69) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29975560 | 0.91 | NPY2R (0.69) | CALCRNPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551533-B2 | Intranasal neuropeptides for use in stress-related impairments | NEW YORK MEDICAL COLLEGE (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220143147-A1 | INTRANASAL NEUROPEPTIDES FOR USE IN STRESS-RELATED IMPAIRMENTS | NEW YORK MEDICAL COLLEGE | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551533-B2 | Intranasal neuropeptides for use in stress-related impairments | NPY5R, NPY1R, NPY2R | CALCR 1093/4885NPY2R 3/4885NPY4R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.